These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 25462133)
1. A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors. Ridoux L; Sémiond DR; Vincent C; Fontaine H; Mauriac C; Sanderink GJ; Oprea C; Kelly L; Clive S Anticancer Drugs; 2015 Mar; 26(3):350-8. PubMed ID: 25462133 [TBL] [Abstract][Full Text] [Related]
2. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO; Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992 [TBL] [Abstract][Full Text] [Related]
3. Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study. Diéras V; Lortholary A; Laurence V; Delva R; Girre V; Livartowski A; Assadourian S; Semiond D; Pierga JY Eur J Cancer; 2013 Jan; 49(1):25-34. PubMed ID: 22975213 [TBL] [Abstract][Full Text] [Related]
4. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Mita AC; Figlin R; Mita MM Clin Cancer Res; 2012 Dec; 18(24):6574-9. PubMed ID: 23091116 [TBL] [Abstract][Full Text] [Related]
5. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177 [TBL] [Abstract][Full Text] [Related]
6. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Bracarda S; Gernone A; Gasparro D; Marchetti P; Ronzoni M; Bortolus R; Fratino L; Basso U; Mazzanti R; Messina C; Tucci M; Boccardo F; Cartenì G; Pinto C; Fornarini G; Mattioli R; Procopio G; Chiuri V; Scotto T; Dondi D; Di Lorenzo G Future Oncol; 2014 May; 10(6):975-83. PubMed ID: 24295376 [TBL] [Abstract][Full Text] [Related]
7. Cabazitaxel for the treatment of castration-resistant prostate cancer. Agarwal N; Sonpavde G; Sartor O Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534 [TBL] [Abstract][Full Text] [Related]
8. Cabazitaxel, a new taxane with favorable properties. Bouchet BP; Galmarini CM Drugs Today (Barc); 2010 Oct; 46(10):735-42. PubMed ID: 21076710 [TBL] [Abstract][Full Text] [Related]
9. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel. Sémiond D; Sidhu SS; Bissery MC; Vrignaud P Cancer Chemother Pharmacol; 2013 Sep; 72(3):515-28. PubMed ID: 23820961 [TBL] [Abstract][Full Text] [Related]
10. Preclinical profile of cabazitaxel. Vrignaud P; Semiond D; Benning V; Beys E; Bouchard H; Gupta S Drug Des Devel Ther; 2014; 8():1851-67. PubMed ID: 25378905 [TBL] [Abstract][Full Text] [Related]
11. Cabazitaxel for the treatment of prostate cancer. Michielsen DP; Braeckman JG; Denis L Expert Opin Pharmacother; 2011 Apr; 12(6):977-82. PubMed ID: 21406025 [TBL] [Abstract][Full Text] [Related]
12. [Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer]. Ecstein-Fraisse E; Su Z Gan To Kagaku Ryoho; 2014 Jul; 41(7):817-22. PubMed ID: 25131866 [TBL] [Abstract][Full Text] [Related]
16. Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer. Sartor O; Halstead M; Katz L Clin Genitourin Cancer; 2010 Dec; 8(1):23-8. PubMed ID: 21208852 [TBL] [Abstract][Full Text] [Related]
17. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Clive S; Woo MM; Nydam T; Kelly L; Squier M; Kagan M Cancer Chemother Pharmacol; 2012 Oct; 70(4):513-22. PubMed ID: 22864948 [TBL] [Abstract][Full Text] [Related]
18. Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells. Azarenko O; Smiyun G; Mah J; Wilson L; Jordan MA Mol Cancer Ther; 2014 Aug; 13(8):2092-103. PubMed ID: 24980947 [TBL] [Abstract][Full Text] [Related]
19. Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. Kort A; Hillebrand MJ; Cirkel GA; Voest EE; Schinkel AH; Rosing H; Schellens JH; Beijnen JH J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Apr; 925():117-23. PubMed ID: 23542607 [TBL] [Abstract][Full Text] [Related]
20. A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function. Azaro A; Rodón J; Machiels JP; Rottey S; Damian S; Baird R; Garcia-Corbacho J; Mathijssen RHJ; Clot PF; Wack C; Shen L; de Jonge MJA Cancer Chemother Pharmacol; 2016 Dec; 78(6):1185-1197. PubMed ID: 27796539 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]